U.S. markets closed

Amneal Pharmaceuticals, Inc. (AMRX)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
2.1000+0.0500 (+2.44%)
At close: 04:00PM EDT
2.0000 -0.10 (-4.76%)
After hours: 05:37PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.0500
Bid2.0500 x 4000
Ask2.1200 x 2900
Day's Range2.0000 - 2.1250
52 Week Range2.0000 - 5.9900
Avg. Volume1,082,685
Market Cap637.402M
Beta (5Y Monthly)1.32
PE Ratio (TTM)210.00
EPS (TTM)0.0100
Earnings DateNov 01, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
32% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for AMRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Amneal Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 12/20/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • Insider Monkey

    10 Best 52-Week Low Small-Cap Stocks to Buy Now

    In this article, we discuss the 10 best 52-week low small-cap stocks to buy now. If you want to skip our discussion on the overall economic environment in the US, go to 5 Best 52-Week Low Small-Cap Stocks to Buy Now. The US stock markets have come under pressure as inflation rose faster than expected […]

  • Business Wire

    Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty

    BRIDGEWATER, N.J., September 06, 2022--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced it has appointed Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty, effective September 6, 2022.

  • Benzinga

    Amneal Seeks FDA Approval For Its Parkinson's Candidate

    Amneal Pharmaceuticals Inc (NYSE: AMRX) submitted a marketing application to the FDA seeking approval for IPX203, an oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for Parkinson's disease. The submission is based on results from the pivotal Phase 3 RISE-PD clinical trial demonstrating more "Good On" time than immediate-release CD/LD. Related Content: Amneal Pharma Posts Mixed Q2 Earnings, Cuts Profit Outlook For 2022. IPX203 was dosed on average three times per day, and